Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pediatric Advisory Committee Will Preview CDK & PD-1 Inhibitors

This article was originally published in The Pink Sheet Daily

Executive Summary

Pediatric subcommittee of the Oncologic Drugs Advisory Committee will discuss pediatric development plans for Novartis’ CDK inhibitor LEE011 and two immune checkpoint inhibitors, Bristol’s nivolumab and Merck’s MK-3475.

You may also be interested in...

Novartis’ CDK Inhibitor May Benefit From Swing Back To Single-Arm Trials

As FDA looks toward more flexible cancer drug development standards, advisory panel indicates Novartis’ proposed pediatric indications for CDK inhibitor could be candidate for single-arm studies.

Cyclacel Novel/Novel Sequence Promising In Tough Cancers

The combination of two novel drugs from Cyclacel inflicts a form of synthetic lethality in which sapacitabine causes DNA defects, rendering tumor cells vulnerable to seliciclib, which thwarts the repair process and is lethal in its own right, the lead investigator reported April 7 at the American Association for Cancer Research meeting in Washington, D.C.

Pfizer Breast Cancer Drug Could Fill Void Left By Avastin Withdrawal

Pfizer’s novel oral CDK 4/6 inhibitor PD-03392991, in combination with letrozole, delivered a statistically and clinically significant increase in median progression-free survival for women with advanced ER+/HER2- breast cancer, according to interim Phase II data presented Dec. 5 at the San Antonio Breast Cancer Symposium.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts